| Chronic Kidney Diseases
Inpefa vs Xphozah
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Inpefa vs Xphozah 10 Mg with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXphozah 10 Mg has a higher rate of injection site reactions vs Inpefa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xphozah 10 Mg but not Inpefa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inpefa
Xphozah 10 Mg
At A Glance
Oral
Daily
SGLT1/SGLT2 inhibitor
Oral
Twice daily
NHE3 inhibitor
Indications
- Heart failure
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
- Chronic Kidney Diseases
Dosing
Heart failure, Diabetes Mellitus, Non-Insulin-Dependent, Chronic Kidney Diseases 200 mg orally once daily, not more than one hour before the first meal; titrate after at least 2 weeks to 400 mg once daily as tolerated; down-titrate to 200 mg as necessary.
Chronic Kidney Diseases 30 mg orally twice daily, taken just prior to the first and last meals of the day; monitor serum phosphorus and adjust dosage as needed for gastrointestinal tolerability.
Contraindications
- History of serious hypersensitivity reaction to INPEFA
- Age under 6 years due to risk of diarrhea and serious dehydration
- Known or suspected mechanical gastrointestinal obstruction
Adverse Reactions
Most common (>=2%) Urinary tract infection, volume depletion, diarrhea, hypoglycemia, dizziness, genital mycotic infection
Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, hypoglycemia with insulin and insulin secretagogues, necrotizing fasciitis of the perineum, genital mycotic infections
Most common (>=5%) Diarrhea (43-53% of patients)
Postmarketing Pruritis, rash, urticaria
Pharmacology
Sotagliflozin is a dual inhibitor of SGLT2 and SGLT1; SGLT2 inhibition reduces renal reabsorption of glucose and sodium (lowering cardiac pre- and afterload and downregulating sympathetic activity), while SGLT1 inhibition reduces intestinal absorption of glucose and sodium.
NHE3 inhibitor; tenapanor is a locally acting inhibitor of sodium/hydrogen exchanger 3 (NHE3), an antiporter on the apical surface of intestinal epithelium, whose inhibition reduces sodium absorption and decreases phosphate absorption by reducing paracellular phosphate permeability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inpefa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (10/12)
Xphozah 10 Mg
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Inpefa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xphozah 10 Mg
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Inpefa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Xphozah 10 Mg
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/fillfill
Inpefa Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Xphozah 10 Mg.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InpefaView full Inpefa profile
Xphozah 10 MgView full Xphozah 10 Mg profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.